Blood component transfusion in critically ill patients.

Area of Science:

• Critical Care Medicine
• Transfusion Medicine
• Hematology

Background:

• Evidence guiding blood component transfusion in critically ill patients remains limited.
• Current transfusion practices often lack robust clinical trial data.
• The Transfusion in Critical Care Trial (TRICC Trial) from 1999 provides key evidence for red blood cell transfusion.

Purpose of the Study:

• To review current evidence for transfusing common blood components.
• To focus on transfusion strategies in non-acutely bleeding critically ill patients.
• To identify evidence gaps in transfusion medicine for critical care.

Main Methods:

• Systematic review of existing literature on blood component transfusion.
• Analysis of evidence from randomized controlled trials and observational studies.
• Focus on critically ill patient populations and specific transfusion scenarios.

Main Results:

• Limited definitive evidence exists for most transfusion practices in the critically ill.
• Red blood cell transfusion triggers are best supported by the TRICC Trial.
• No randomized controlled trials address outcomes for frozen plasma or platelet transfusion thresholds in critical care.

Conclusions:

• A strategy of minimizing blood component transfusion is recommended due to inherent risks.
• A red blood cell transfusion trigger of 70 g/L is acceptable for non-acutely bleeding critically ill patients.
• Higher red blood cell transfusion thresholds (80-90 g/L) may be considered for high-risk patients; evidence for plasma and platelet transfusion is insufficient.